The Short Answer
Patients with TSC-associated angiomyolipomas (often multiple, progressive tumors) may benefit from everolimus (Afinitor) or sirolimus (Rapamune), which slow tumor growth by 50–60% and reduce bleeding risk. These mTOR inhibitors are standard for TSC-AML; sporadic AMLs rarely need medication [3][7].
Everolimus is an mTOR inhibitor—a drug that blocks a growth pathway inside tumor cells. In the EXIST-2 trial, TSC patients on everolimus 10 mg daily showed 53% reduction in AML volume over 4 years, with stable kidney function. The drug is well-tolerated long-term, though it requires monthly lab monitoring (lipids, renal function, glucose) [7].
Sirolimus (Rapamune) works similarly and is an alternative if everolimus causes side effects. Both drugs require lifelong dosing for TSC-AML because tumors regrow if you stop. Monthly blood work and imaging every 6 months are standard to track response and catch any complications early [3][7].
Sporadic (non-TSC) angiomyolipomas almost never need medication—observation and embolization/surgery are sufficient. TSC patients have multiple AMLs and higher bleeding risk, so systemic therapy makes sense. Cost is high ($8,000–15,000/month), but insurance often covers it for TSC-AML given the proven benefit [3][7].
Try This Today
If you have TSC and multiple AMLs, ask your nephrologist or urologist: 'Should I start everolimus or sirolimus, and what labs will I need monthly?' Discuss the cost, side effects (mouth sores, high cholesterol, low blood counts), and how long you'll stay on the drug [7].